IFC Holdings Incorporated FL decreased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 79.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,950 shares of the biopharmaceutical company’s stock after selling 65,300 shares during the period. IFC Holdings Incorporated FL’s holdings in Halozyme Therapeutics were worth $217,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in the stock. Teacher Retirement System of Texas acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth $129,000. First Trust Advisors LP raised its stake in shares of Halozyme Therapeutics by 353.8% in the second quarter. First Trust Advisors LP now owns 71,106 shares of the biopharmaceutical company’s stock worth $912,000 after buying an additional 55,437 shares during the last quarter. Granite Investment Partners LLC acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth $7,250,000. Schwab Charles Investment Management Inc. raised its stake in shares of Halozyme Therapeutics by 9.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 511,806 shares of the biopharmaceutical company’s stock worth $6,562,000 after buying an additional 46,040 shares during the last quarter. Finally, Pictet Asset Management Ltd. raised its stake in shares of Halozyme Therapeutics by 6.3% in the second quarter. Pictet Asset Management Ltd. now owns 1,548,625 shares of the biopharmaceutical company’s stock worth $18,274,000 after buying an additional 91,199 shares during the last quarter. Institutional investors and hedge funds own 81.09% of the company’s stock.
Halozyme Therapeutics, Inc. (HALO) opened at 11.90 on Wednesday. The company’s market cap is $1.59 billion. The firm’s 50-day moving average is $12.96 and its 200 day moving average is $13.14. Halozyme Therapeutics, Inc. has a 1-year low of $8.18 and a 1-year high of $15.20.
Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. The company had revenue of $33.80 million during the quarter, compared to analysts’ expectations of $31.76 million. During the same quarter last year, the firm earned ($0.21) EPS. Halozyme Therapeutics’s revenue for the quarter was up 1.2% on a year-over-year basis. Analysts predict that Halozyme Therapeutics, Inc. will post ($0.97) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Halozyme Therapeutics, Inc. (HALO) Shares Sold by IFC Holdings Incorporated FL” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://stocknewstimes.com/2017/08/16/halozyme-therapeutics-inc-halo-shares-sold-by-ifc-holdings-incorporated-fl.html.
HALO has been the subject of a number of recent research reports. Barclays PLC restated an “overweight” rating and issued a $16.00 price objective on shares of Halozyme Therapeutics in a report on Friday, June 23rd. Piper Jaffray Companies set a $20.00 target price on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 10th. BidaskClub downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, July 1st. Jefferies Group LLC reaffirmed an “underperform” rating and issued a $7.00 target price (up from $6.75) on shares of Halozyme Therapeutics in a research note on Thursday, August 10th. Finally, Zacks Investment Research raised shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, May 12th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $14.75.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
